Below are the most recent publications written about "Multiple Myeloma" by people in Profiles.
-
Joshi N, Li J, Karambelkar A, Boere P. Isolated Abducens Nerve Palsy: A Rare Manifestation of Recurrent Extramedullary Myeloma. J Radiol Case Rep. 2024; 18(1):14-19.
-
Afrough A, Hashmi H, Hansen DK, Sidana S, Ahn C, Peres LC, Dima D, Freeman CL, Puglianini OC, Kocoglu MH, Atrash S, Voorhees PM, Shune L, McGuirk JP, Simmons G, Sborov DW, Davis JA, Kaur G, Sannareddy A, Ferreri CJ, Gaballa MR, Goldsmith S, Nadeem O, Midha S, Wagner CB, Locke FL, Patel KK, Khouri J, Anderson LD, Lin Y. Real-world impact of bridging therapy on outcomes of ide-cel for myeloma in the U.S. Myeloma Immunotherapy Consortium. Blood Cancer J. 2024 Apr 12; 14(1):63.
-
Frosch ZAK, Meshack C, Meeker C, Varshavsky-Yanovsky A, Khanal R, Bromberg M, Chandar A, Quien E, Carter J, Nakhoda SK, Messmer M, Montgomery C, Incorvati JA, Ali ND, Styler MJ, Fang CY. YIA24-002: Patients' Perspectives on Being Treated by Multiple Care Teams for Autologous Transplant/CAR-T Eligible Lymphoma and Multiple Myeloma. J Natl Compr Canc Netw. 2024 Apr 05; 22(2.5).
-
Mignano SE, Pascal V, Odioemene NE, Forehand W, Javaugue V, Said SM, Sethi S, Sirac C, Nasr SH. Monoclonal Immunoglobulin Crystalline Membranous Nephropathy. Am J Kidney Dis. 2024 Jul; 84(1):120-125.
-
Hasanali ZS, Razzo B, Susanibar-Adaniya SP, Garfall AL, Stadtmauer EA, Cohen AD. Chimeric Antigen Receptor T Cells in the Treatment of Multiple Myeloma. Hematol Oncol Clin North Am. 2024 04; 38(2):383-406.
-
Razzo B, Garfall AL, Cohen AD. Options at the time of relapse after anti-BCMA therapy. Hematology Am Soc Hematol Educ Program. 2023 Dec 08; 2023(1):450-458.
-
Fish AM, Kirupaharan P, Scharf ML. An Incidental Finding of Pulmonary Cement Embolism Four Weeks After Vertebroplasty in a 50-Year-Old Man with Multiple Myeloma. Am J Case Rep. 2023 Dec 01; 24:e941716.
-
Binder AF, Walker CJ, Mark TM, Baljevic M. Impacting T-cell fitness in multiple myeloma: potential roles for selinexor and XPO1 inhibitors. Front Immunol. 2023; 14:1275329.
-
Cowan AJ, Pont MJ, Sather BD, Turtle CJ, Till BG, Libby EN, Coffey DG, Tuazon SA, Wood B, Gooley T, Wu VQ, Voutsinas J, Song X, Shadman M, Gauthier J, Chapuis AG, Milano F, Maloney DG, Riddell SR, Green DJ. ?-Secretase inhibitor in combination with BCMA chimeric antigen receptor T-cell immunotherapy for individuals with relapsed or refractory multiple myeloma: a phase 1, first-in-human trial. Lancet Oncol. 2023 Jul; 24(7):811-822.
-
Richardson K, Keam SP, Zhu JJ, Meyran D, D'Souza C, Macdonald S, Campbell K, Robbins M, Bezman NA, Todd K, Quach H, Ritchie DS, Harrison SJ, Prince HM, Trapani JA, Jenkins MR, Beavis PA, Darcy PK, Neeson PJ. The efficacy of combination treatment with elotuzumab and lenalidomide is dependent on crosstalk between natural killer cells, monocytes and myeloma cells. Haematologica. 2023 01 01; 108(1):83-97.